Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

Also called NCT01407003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose other
Phase
Phase 1/2
Enrolled
  • 138 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01407003
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01407003. Randomized; double masking; primary purpose other. Start 2011-06 (registry gives no type); primary completion 2013-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
LIK066
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01407003
Content hash
d3a8a48a9529f7cba0ccf0a2d9f97f3401cfda84b2d7d72a08cf379d8374c490